Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer

NCT03462342 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT03462342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03462342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer
Lead sponsor
University of Pennsylvania
Phase
Phase 2
Overall status
Completed
Start date
March 9, 2018
Completion date
July 21, 2025
Enrollment
123 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

high grade serous carcinoma